Delivery Order SPE2DB20D1100-SPE2DB25FD6N6
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at approximately $43.3K to AmerisourceBergen Drug Corp for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pens on July 25, 2025, with an ultimate completion date of July 28, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside contract and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract falls under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $11,456.86 to AmerisourceBergen Drug Corp for the supply of Zepbound (tirzepatide) 7.5 mg/0.5 mL pens on July 25, 2025, with completion targeted for July 28, 2025. This firm fixed price delivery order represents a non-competitive set-aside and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award is issued under the company's existing Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $7,738.94 to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Zepbound (tirzepatide) 10 mg/0.5 mL pre-filled pens. The contract utilizes firm fixed pricing with no set-aside designation, indicating competitive award status. AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania serves as the place of performance. This delivery order is a child contract under the company's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $11,057.47 to AmerisourceBergen Drug Corp for the supply of Zepbound (tirzepatide) 10 mg/0.5 ml pen injections on August 8, 2025. This firm fixed-price delivery order, with a completion date of August 11, 2025, was competitively awarded with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform work at its corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $35,643.13 to AmerisourceBergen Drug Corp for the supply of Zepbound (tirzepatide) 7.5 mg/0.5 mL pens on August 5, 2025, with an ultimate completion date of August 6, 2025. This competitive, firm fixed-price delivery order carries no set-aside designation and will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a single delivery order under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $14,950.78 to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Zepbound (tirzepatide) 15 mg/0.5 mL pen injectors. This competitively awarded, firm fixed-price contract is scheduled for completion by July 24, 2025, with performance taking place at AmerisourceBergen's corporate offices in Conshohocken, Pennsylvania. The contract represents a single delivery order issued under a larger procurement vehicle and carries...
- The Defense Logistics Agency awarded a delivery order valued at $4,575.48 to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pre-filled pens. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and carries an ultimate completion date of July 28, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary headquarters and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pens valued at $8,763.90. This contract represents a firm fixed-price delivery order with an ultimate completion date of July 29, 2025, and will be fulfilled at the contractor's Conshohocken, Pennsylvania facility. The award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's competitive...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,538.13 to AmerisourceBergen Drug Corp for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pens on August 4, 2025. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of August 5, 2025, and represents a direct pharmaceutical procurement to support federal healthcare needs. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania serves as the place of performance. This delivery...
- The Defense Logistics Agency awarded a $19,064.54 delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound (tirzepatide) 10 mg/0.5 mL pen injections on July 25, 2025. This firm fixed-price delivery order, with an ultimate completion date of July 28, 2025, was competitively awarded with no set-aside designation. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters and primary...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FD6N6Delivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order on July 25, 2025, for supply of Zepbound (tirzepatide) 10 mg/0.5 mL pens with a ceiling value of $1,143.87. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of July 28, 2025, and will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical, a $999.9 billion prime vendor agreement running through December 2026 that enables the company to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement through competitively awarded contracts with the Defense Logistics Agency and its Medical Supply Chain. The company's extensive federal contract portfolio demonstrates its capability to fulfill diverse pharmaceutical needs, including specialty medications, brand-name and generic drugs, vaccines, and medical devices across multiple therapeutic domains. This delivery order for Zepbound—a diabetes and weight management medication—reflects the company's role in supplying pharmaceutical products to support the Defense Health Agency and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 7/25/25 |